Rigel Pharmaceuticals, Inc.
2,3-Disubstituted pyridine compounds as TGF-.beta. inhibitors and methods of use
Last updated:
Abstract:
The invention described herein comprises compounds and a method of treating cancer comprising administering to a subject having cancer one of the compounds in conjunction with another therapeutic treatment of cancer. The compounds inhibit signaling by a member of the TGF-.beta. superfamily such as Nodal or Activin.
Status:
Grant
Type:
Utility
Filling date:
16 Jan 2019
Issue date:
8 Dec 2020